{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:26:46Z","timestamp":1714696006449},"posted":{"date-parts":[[2023,3,10]]},"group-title":"In Review","reference-count":0,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,3,4]]},"abstract":"<title>Abstract<\/title>\n        <p>Mantle cell lymphoma (MCL) is a heterogeneous disease with a poor prognosis. Despite years of research in MCL, relapse occurs in patients with current therapeutic options necessitating the development of novel therapeutic agents. Previous attempts to pharmacologically inhibit SRC-3 show effectiveness <italic>in vivo<\/italic> and <italic>in vitro<\/italic> in other B cell lymphomas, and previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin\u2019s lymphoma patients. This suggests that SRC-3 may play a role in the progression of B cell lymphoma and that the development of selective SRC inhibitors should be investigated. This study aimed to investigate novel SRC-3 inhibitors, SI-10 and SI-12, in mantle cell lymphoma. The cytotoxic effects of SI-10 and SI-12 were evaluated in a panel of MCL cell lines <italic>in vitro<\/italic> by resazurin assay. The in vivo efficacy of SI-10 was confirmed in two ibrutinib-resistant models: an immunocompetent disseminated A20 mouse model of B-cell lymphoma and a human PDX model of MCL. SI-10 treatment resulted in dose-dependent cytotoxicity in a panel of MCL cell lines <italic>in vitro<\/italic>. Notably, SI-10 treatment also resulted in a significant extension of survival in vivo with low toxicity in both ibrutinib-resistant murine models. We have investigated SI-10 as a novel anti-lymphoma compound via the inhibition of SRC-3 activity. These findings indicate that targeting SRC-3 should be investigated in combination with current clinical therapeutics as a novel strategy to expand the therapeutic index and to improve lymphoma outcomes.<\/p>","DOI":"10.21203\/rs.3.rs-2653461\/v1","type":"posted-content","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:17:53Z","timestamp":1678407473000},"source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma\u00a0"],"prefix":"10.21203","author":[{"given":"Imani","family":"Bijou","sequence":"first","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Lu","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby","family":"Sloan","sequence":"additional","affiliation":[{"name":"The James Cancer Hospital and Solove Research Institute, The Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"The James Cancer Hospital and Solove Research Institute, The Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Lonard","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert W.","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2653461\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2653461\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T01:46:52Z","timestamp":1714614412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2653461\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2653461\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1371\/journal.pone.0289902","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,3,10]]},"subtype":"preprint"}}